Biomedical subjects

J Dahlgren

Publications and source records attributed to J Dahlgren.

21 records · Page 2Linked to original sources

PubMedDate not supplied

In vitro activity of lomefloxacin (SC 47111 or NY-198), a new quinolone antimicrobial, against clinical isolates of common pathogens.

The lomefloxacin antibacterial activity was assessed against 442 clinical isolates of common bacterial pathogens and compared to the previously studied activity of ciprofloxacin, imipenem, norfloxacin, and other commonly used antibacterials. Lomefloxacin showed activity against the species of Enterobacteriaceae tested at a concentration equal to or below that of the most commonly used agents. Activity was lower against Pseudomonas species as well as most Gram-positive isolates tested with the exception of Staphylococcus aureus. Streptococcal strains were least susceptible. The results of this study support previous reports of excellent antimicrobial activity for lomefloxacin, especially against Gram-negative organisms.

4-Quinolones↗

PubMedDate not supplied

Abdominal pain in lead workers.

Thirty-four lead smelter workers with excessive lead absorption were evaluated and followed. Abdominal pain was present in 27 patients. Fifteen patients who had left the site of lead exposure experienced persisting abdominal pain for as long as 29 months; some of these demonstrated acceptable levels of lead in blood. There is no correlation between lead levels and persisting pain. Twenty-three patients developed abdominal pain with blood lead lower than 80 microgram/100 ml while working. Four out of 15 patients with persisting abdominal pain had blood lead between 40 and 60 microgram/100 ml while working. Typical lead-induced abdominal pain is a sensitive symptom of intoxication and may be a criterion for removal from exposure regardless of blood lead levels.

Abdomen↗

PubMedDate not supplied

Red-wine polyphenols and inhibition of platelet aggregation: possible mechanisms, and potential use in health promotion and disease prevention.

An extract from red-wine grape fermentation, ANOX has been developed as a source of red-wine polyphenols, which are thought to inhibit several of the pathogenic pathways that lead to cardiovascular disease. New data indicate that this extract has a significantly greater effect than either red wine or red-wine powder on the inhibition of platelet aggregation in vitro. Based on this data, about 300 - 500 mg of the extract is equivalent to the daily dose of red-wine polyphenols that appears to protect against cardiovascular disease. The possible synergistic effect of red-wine polyphenols with vitamin C, their vasorelaxing activity and their possible role in preventing over-crosslinking of connective tissues (premature ageing) are considered. The extract contains standardized amounts of the whole spectrum of polyphenolic compounds found in red wine and may provide a valuable reference substance in clinical investigations of the physiological actions of plant polyphenols; its potential use in functional nutrition and preventive medicine is also discussed.

Animals↗